What the FDA labels say about taking them together
Cyclosporine and dabigatran
Cyclosporine's FDA label of August 10, 2026 names dabigatran in its drug interactions section; the dabigatran labels PlainMeds reads (2) do not name cyclosporine. The cyclosporine label: “Cyclosporine may reduce the clearance of digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (statins), aliskiren, bosentan, dabigatran, repaglinide, NSAIDs, sirolimus, etoposide, and other drugs.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the dabigatran FDA label on DailyMed (effective June 25, 2025, Boehringer Ingelheim Pharmaceuticals Inc.).
What does the cyclosporine label say about dabigatran?
Cyclosporine label, drug interactionsCyclosporine may reduce the clearance of digoxin, colchicine, prednisolone, HMG-CoA reductase inhibitors (statins), aliskiren, bosentan, dabigatran, repaglinide, NSAIDs, sirolimus, etoposide, and other drugs.
Source: FDA drug label (Sandimmune, NDA050573), Novartis Pharmaceuticals Corporation, effective July 10, 2026 (SPL set 5e5926a7-1de0-4b54-a5c0-286b6200ff82), via openFDA
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the dabigatran label say about cyclosporine?
Dabigatran's label (effective June 25, 2025) and its 1 other brand-application label do not name cyclosporine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pradaxa), Boehringer Ingelheim Pharmaceuticals Inc., effective June 25, 2025 (SPL set ba74e3cd-b06f-4145-b284-5fd6b84ff3c9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Dabigatran | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.795 per capsule 150 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once